Ardelyx Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
Ardelyx (ARDX) Misses Q3 EPS by 22c
November 12, 2015 9:27 AM ESTArdelyx (NASDAQ: ARDX) reported Q3 EPS of ($0.70), $0.22 worse than the analyst estimate of ($0.48).
Two key clinical development programs accelerated, tenapanor in IBS-C and RDX022 in hyperkalemia Initiation of a second Phase 3 clinical trial for tenapanor in IBS-C expected December 2015 Results of a... More
